In 2011, sales of new drugs introduced 2007–2011 were $40 billion, or 7% of global sales not including generics and over-the-counter drugs. Small molecule drugs represented 56% of sales, and oncology products and immunomodulators constituted 15%. In 2016, sales of new drugs launched 2011–2016 are expected to reach $58 billion, or 9% of global sales. For drugs introduced 2011–2016, small molecule drugs are expected to account for 65% of sales in 2016, and oncology products and immunomodulators are expected to make up 29%. Despite this growth, the number of new drugs in development in 2011 fell 3.9% to 7,408 from the high point in 2009. The number of new drugs in the preclinical stage fell 11% from 2009 to 2011, but the number in Phase III grew nearly 9% per year for that period. An average of about 35 new drugs are estimated to be launched annually 2011–2016.

Source: Nature Reviews Drug Discovery